How to appeal a Cigna myasthenia gravis & cidp denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for myasthenia gravis & cidp

Cited policy: Cigna Rystiggo (rozanolixizumab-noli) PA — FcRn Antagonist for AChR+ or MuSK+ gMG

Generalized MG with anti-AChR-Ab+ OR anti-MuSK-Ab+ documented serology. MG-ADL >=3 (per MycarinG entry). Inadequate response or intolerance to >=1 IS. Neurologist Rx. Reauth at 6 mo with response.

How Cigna denies myasthenia gravis & cidp — and how to counter it

Where Cigna pushes back: 1) MuSK-Ab+ patients should try rituximab off-label first; 2) Step-therapy through Vyvgart before Rystiggo; 3) ADL threshold issue.

Counter-arguments that hold up: MycarinG (Bril Lancet Neurol 2023) — Phase 3 Rystiggo in AChR-Ab+ AND MuSK-Ab+ gMG; supported FDA approval Jun 27, 2023. Rystiggo is the FIRST FcRn antagonist with FDA-labeled MuSK-Ab+ indication — Vyvgart label is AChR-Ab+ only. For MuSK+ patients, Rystiggo is on-label whereas Vyvgart is off-label. Rituximab is also off-label per IST 2020 (preferred for MuSK+ but not FDA-approved). Class step-therapy across distinct FcRn agents lacks clinical basis when label scope differs.

What Cigna typically denies for myasthenia gravis & cidp

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For myasthenia gravis & cidp, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the myasthenia gravis & cidp treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Soliris (MG)
• Ultomiris (MG)
• Vyvgart IV (MG)
• Vyvgart Hytrulo (MG)
• Rystiggo (MG)
• Zilbrysq (MG)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.